Skip to main content
. Author manuscript; available in PMC: 2020 Dec 8.
Published in final edited form as: J Leukoc Biol. 2020 Feb 5;107(6):1069–1079. doi: 10.1002/JLB.5MA0120-228R

FIGURE 1. Humanized NSG-A24:02 transgenic mice models.

FIGURE 1

Schematic overview of the in vivo experiment for nontumor bearing (A) and K562 HLA-A*24:02 tumor-bearing mice (B). Nontumor bearing NSG-A24:02 mice were irradiated at day −1 and received 2 injections of TEG011 or TEG-LM1 mock on days 1 and 6. Irradiated tumor-bearing NSG-A24:02 mice were injected with K562 HLA-A*24:02 luciferase tumor cells on day 0 followed by received 2 injections of TEG011 or TEG-LM1 mock on days 1 and 6. Mice were monitored weekly and sacrificed at day 72 or earlier when humane endpoint (HEP) is reached